10 results on '"Aung Swi Prue"'
Search Results
2. Assessment of Plasmodium falciparum Artemisinin Resistance Independent of
- Author
-
Maisha Khair, Nima, Angana, Mukherjee, Saiful Arefeen, Sazed, Muhammad Riadul Haque, Hossainey, Ching Swe, Phru, Fatema Tuj, Johora, Innocent, Safeukui, Anjan, Saha, Afsana Alamgir, Khan, Aung Swi Prue, Marma, Russell E, Ware, Narla, Mohandas, Barbara, Calhoun, Rashidul, Haque, Wasif Ali, Khan, Mohammad Shafiul, Alam, and Kasturi, Haldar
- Subjects
Bangladesh ,artemisinin ,parasitic diseases ,malaria ,antimalarial agents ,Research Article - Abstract
Emerging resistance to artemisinin drugs threatens the elimination of malaria. Resistance is widespread in South East Asia (SEA) and Myanmar. Neighboring Bangladesh, where 90% of infections occur in the Chittagong Hill Tracts (CHTs), lacks recent assessment. We undertook a prospective study in the sole district-level hospital in Bandarban, a CHT district with low population densities but 60% of reported malaria cases. Thirty patients presented with malaria in 2018. An increase to 68 patients in 2019 correlated with the district-level rise in malaria, rainfall, humidity, and temperature. Twenty-four patients (7 in 2018 and 17 in 2019) with uncomplicated Plasmodium falciparum monoinfection were assessed for clearing parasites after starting artemisinin combination therapy (ACT). The median (range) time to clear half of the initial parasites was 5.6 (1.5 to 9.6) h, with 20% of patients showing a median of 8 h. There was no correlation between parasite clearance and initial parasitemia, blood cell counts, or mutations of P. falciparum gene Pfkelch13 (the molecular marker of artemisinin resistance [AR]). The in vitro ring-stage survival assay (RSA) revealed one (of four) culture-adapted strains with a quantifiable resistance of 2.01% ± 0.1% (mean ± standard error of the mean [SEM]). Regression analyses of in vivo and in vitro measurements of the four CHT strains and WHO-validated K13 resistance mutations yielded good correlation (R2 = 0.7; ρ = 0.9, P
- Published
- 2022
3. Case Report: A Case of Primaquine-Induced Hemoglobinuria in Glucose-6-Phosphate Dehydrogenase Deficient Malaria Patient in Southeastern Bangladesh
- Author
-
Kamala Thriemer, Ching Swe Phru, Mohammad Golam Kibria, Wasif A. Khan, Ari W. Satyagraha, Mohammad Shafiul Alam, M. M. Aktaruzzaman, Nusrat Jahan, Benedikt Ley, Mahtab Uddin Chowdhury, Hisni Rahmat, and Aung Swi Prue
- Subjects
Male ,medicine.medical_specialty ,Blood transfusion ,Primaquine ,medicine.medical_treatment ,G6PD activity ,030231 tropical medicine ,Hemoglobinuria ,Gastroenterology ,03 medical and health sciences ,chemistry.chemical_compound ,Antimalarials ,0302 clinical medicine ,Chloroquine ,Virology ,Internal medicine ,parasitic diseases ,medicine ,Glucose-6-phosphate dehydrogenase ,Humans ,Blood Transfusion ,Child ,business.industry ,Articles ,medicine.disease ,Malaria ,Infectious Diseases ,Glucosephosphate Dehydrogenase Deficiency ,chemistry ,Parasitology ,Hemoglobin ,business ,medicine.drug - Abstract
We herein report the first case of Mediterranean glucose-6-phosphate dehydrogenase (G6PD) variant from Bangladesh. A boy had been admitted to hospital and was diagnosed with uncomplicated Plasmodium vivax infection and treated with 30 mg/kg body weight (BW) chloroquine for 3 days and 4.8 mg/kg BW primaquine (PQ) to be taken over 14 days. The boy was discharged but represented 4 days later with severe hemoglobinuria and fatigue. Hemoglobin was measured at 6.0 g/dL and serum bilirubin was at 5.6 mg/dL, although malaria microscopy was negative. The boy had taken the 4-fold recommended daily dose of PQ and was treated with two fresh blood transfusions. Subsequent molecular analysis showed the boy to have the Mediterranean G6PD variant and a G6PD activity of 0.93 U/gHb.
- Published
- 2019
4. Little Polymorphism at the K13 Propeller Locus in Worldwide Plasmodium falciparum Populations Prior to the Introduction of Artemisinin Combination Therapies
- Author
-
Hiroyoshi Endo, Wah Win Htike, Haruki Uemura, Nobuyuki Takahashi, Richard Culleton, Marcelo U. Ferreira, Lek Dysoley, Mathieu Ndounga, Takahiro Tsukahara, Aung Swi Prue Marma, Masatoshi Nakamura, Mawuli Dzodzomenyo, Carol W. Hunja, Toshihiro Mita, Jun Ohashi, Anders Björkman, Jun Kobayashi, Francis Hombhanje, Willis Akhwale, Akira Kaneko, and Zin Zayar Win
- Subjects
0301 basic medicine ,Nonsynonymous substitution ,Plasmodium falciparum ,030106 microbiology ,030231 tropical medicine ,Population ,Epidemiology and Surveillance ,Nucleotide diversity ,Antimalarials ,03 medical and health sciences ,Negative selection ,0302 clinical medicine ,parasitic diseases ,medicine ,Humans ,Pharmacology (medical) ,Malaria, Falciparum ,Artemisinin ,education ,MALÁRIA ,Gene ,Pharmacology ,Genetics ,education.field_of_study ,Polymorphism, Genetic ,biology ,Haplotype ,biology.organism_classification ,Artemisinins ,Genetics, Population ,Infectious Diseases ,Mutation ,medicine.drug - Abstract
The emergence and spread of artemisinin-resistant Plasmodium falciparum is of huge concern for the global effort toward malaria control and elimination. Artemisinin resistance, defined as a delayed time to parasite clearance following administration of artemisinin, is associated with mutations in the Pfkelch13 gene of resistant parasites. To date, as many as 60 nonsynonymous mutations have been identified in this gene, but whether these mutations have been selected by artemisinin usage or merely reflect natural polymorphism independent of selection is currently unknown. To clarify this, we sequenced the Pfkelch13 propeller domain in 581 isolates collected before (420 isolates) and after (161 isolates) the implementation of artemisinin combination therapies (ACTs), from various regions of endemicity worldwide. Nonsynonymous mutations were observed in 1% of parasites isolated prior to the introduction of ACTs. Frequencies of mutant isolates, nucleotide diversity, and haplotype diversity were significantly higher in the parasites isolated from populations exposed to artemisinin than in those from populations that had not been exposed to the drug. In the artemisinin-exposed population, a significant excess of dN compared to dS was observed, suggesting the presence of positive selection. In contrast, pairwise comparison of dN and dS and the McDonald and Kreitman test indicate that purifying selection acts on the Pfkelch13 propeller domain in populations not exposed to ACTs. These population genetic analyses reveal a low baseline of Pfkelch13 polymorphism, probably due to purifying selection in the absence of artemisinin selection. In contrast, various Pfkelch13 mutations have been selected under artemisinin pressure.
- Published
- 2016
5. Spontaneous Mutations in the Plasmodium falciparum Sarcoplasmic/ Endoplasmic Reticulum Ca 2+ -ATPase (PfATP6) Gene among Geographically Widespread Parasite Populations Unexposed to Artemisinin-Based Combination Therapies
- Author
-
Kazuyuki Tanabe, Toshihiro Horii, Manada Afsharpad, Milijaona Randrianarivelojosia, Toshihiro Mita, Aung Swi Prue Marma, Sedigheh Zakeri, Nirianne Marie Q. Palacpac, and Akira Kaneko
- Subjects
Pharmacology ,Genetics ,0303 health sciences ,SERCA ,biology ,030231 tropical medicine ,Haplotype ,Plasmodium falciparum ,Single-nucleotide polymorphism ,biology.organism_classification ,3. Good health ,Minor allele frequency ,03 medical and health sciences ,0302 clinical medicine ,Infectious Diseases ,parasitic diseases ,medicine ,Pharmacology (medical) ,Artemisinin ,Gene ,Allele frequency ,030304 developmental biology ,medicine.drug - Abstract
Recent reports on the decline of the efficacy of artemisinin-based combination therapies (ACTs) indicate a serious threat to malaria control. The endoplasmic/sarcoplasmic reticulum Ca 2+ -ATPase ortholog of Plasmodium falciparum (PfSERCA) has been suggested to be the target of artemisinin and its derivatives. It is assumed that continuous artemisinin pressure will affect polymorphism of the PfSERCA gene ( serca ) if the protein is the target. Here, we investigated the polymorphism of serca in parasite populations unexposed to ACTs to obtain baseline information for the study of potential artemisinin-driven selection of resistant parasites. Analysis of 656 full-length sequences from 13 parasite populations in Africa, Asia, Oceania, and South America revealed 64 single nucleotide polymorphisms (SNPs), of which 43 were newly identified and 38 resulted in amino acid substitutions. No isolates showed L263E and S769N substitutions, which were reportedly associated with artemisinin resistance. Among the four continents, the number of SNPs was highest in Africa. In Africa, Asia, and Oceania, common SNPs, or those with a minor allele frequency of ≥0.05, were less prevalent, with most SNPs noted to be continent specific, whereas in South America, common SNPs were highly prevalent and often shared with those in Africa. Of 50 amino acid haplotypes observed, only one haplotype (3D7 sequence) was seen in all four continents (64%). Forty-eight haplotypes had frequencies of less than 5%, and 40 haplotypes were continent specific. The geographical difference in the diversity and distribution of serca SNPs and haplotypes lays the groundwork for assessing whether some artemisinin resistance-associated mutations and haplotypes are selected by ACTs.
- Published
- 2011
6. High prevalence of sulfadoxine/pyrimethamine resistance alleles in Plasmodium falciparum parasites from Bangladesh
- Author
-
Aung Swi Prue Marma, Takahiro Tsukahara, Hiroyoshi Endo, Hideaki Eto, Toshihiro Mita, and Sumon Sarker
- Subjects
Male ,Adolescent ,Genotype ,Sulfadoxine ,medicine.medical_treatment ,Plasmodium falciparum ,Drug Resistance ,Protozoan Proteins ,DHPS ,Biology ,Polymerase Chain Reaction ,Antimalarials ,Parasitic Sensitivity Tests ,parasitic diseases ,Dihydrofolate reductase ,Prevalence ,medicine ,Animals ,Humans ,Malaria, Falciparum ,Child ,Alleles ,Genetics ,Bangladesh ,medicine.disease ,biology.organism_classification ,Virology ,Sulfadoxine/pyrimethamine ,Drug Combinations ,Tetrahydrofolate Dehydrogenase ,Pyrimethamine ,Infectious Diseases ,Child, Preschool ,biology.protein ,Female ,Parasitology ,Multidrug Resistance-Associated Proteins ,Malaria ,medicine.drug - Abstract
In Bangladesh, despite the official introduction of artemisinin combination therapy in 2004, chloroquine+sulfadoxine/pyrimethamine has been used for the treatment of uncomplicated malaria. To assess the distribution of pfcrt, pfmdr1, dhfr, and dhps genotypes in Plasmodium falciparum, we conducted hospital- and community-based surveys in Bandarban, Bangladesh (near the border with Myanmar) in 2007 and 2008. Using nested PCR followed by digestion, 139 P. falciparum isolates were genotyped. We found fixation of a mutation at position 76 in pfcrt and low prevalence of a mutation at position 86 in pfmdr1. In dhfr, the highest pyrimethamine resistant genotype quadruple mutant was found in 19% of isolates, which is significantly higher prevalence than reported in a previous study in Khagrachari (1%) in 2002. Microsatellite haplotypes flanking dhfr of the quadruple mutants in Bangladesh were identical or very similar to those found in Thailand and Cambodia, indicating a common origin for the mutant in these countries. These observations suggest that the higher prevalence of the dhfr quadruple mutant in Bandarban is because of parasite migration from Myanmar. However, continuous use of sulfadoxine/pyrimethamine would have also played a role through selection for the dhfr quadruple mutant. These results indicate an urgent need to collect molecular epidemiological information regarding dhfr and dhps genes, and a review of current sulfadoxine/pyrimethamine usage with the aim of avoiding the widespread distribution of high levels of resistant parasites in Bangladesh.
- Published
- 2010
7. Glucose-6-Phosphate Dehydrogenase (G6PD) Variants in Three Minority Ethnic Groups in Central and Northern Vietnam
- Author
-
Toshihiro Mita, Pham Hoang Trung, Nguyen Min Hung, Aung Swi Prue Marma, Takatoshi Kobayakawa, Hiroyuki Matsuoka, Hideaki Eto, Le Minh Dao, Vo Nhu Phuong, and Ta Thi Tinh
- Subjects
Genetics ,congenital, hereditary, and neonatal diseases and abnormalities ,Public Health, Environmental and Occupational Health ,Ethnic group ,nutritional and metabolic diseases ,Biology ,Common ancestry ,Thais ,biology.organism_classification ,chemistry.chemical_compound ,Infectious Diseases ,G6PD VIANGCHAN ,chemistry ,hemic and lymphatic diseases ,parasitic diseases ,Genetic variation ,Glucose-6-phosphate dehydrogenase ,G6PD CANTON - Abstract
Community-based surveys for the detection of glucose-6-phosphate dehydogenase (G6PD) deficiency were conducted at three villages in central and northern Vietnam from 2001 to 2006. A total of 799 male individuals belonging to three ethnic groups (Raglai, Pako, and Khomu) were tested for G6PD enzyme activity and 32 G6PD deficient individuals were detected. The prevalence of G6PD deficiency in Raglai, Pako, and Khomu was 2.1% (9⁄438), 7.7% (16⁄208), and 4.6% (7⁄153), respectively. In Raglai, G6PD Viangchan was found to be dominant (8⁄9, 88.9%), followed by G6PD Canton (1⁄9, 11.1%). In Pako, a total of 16 G6PD deficient cases showed G6PD Viangchan variant. All analyzed samples (7⁄7, 100%) showed the G6PD Union variant in the Khomu ethnic group. Our study suggests that the Raglai and Pako people share a common ancestry with Cambodians, Laotians, and Thais. On the other hand, the appearance of G6PD Union among Khomu people suggests that they originate from a different ancestry.
- Published
- 2009
8. In vitro Interaktionsstudien mit Azithromycin und Dihydroartemisinin in Plasmodium falciparum Isolaten aus Bangladesh
- Author
-
Kamala Thriemer, Selim Akther, Wasif A. Khan, Harald Noedl, Peter Starzengruber, Mark M. Fukuda, Rashidul Haque, Matthias G. Vossen, and Aung Swi Prue Marma
- Subjects
Drug ,biology ,Combination therapy ,business.industry ,medicine.medical_treatment ,media_common.quotation_subject ,Dihydroartemisinin ,Plasmodium falciparum ,General Medicine ,Pharmacology ,medicine.disease ,Azithromycin ,biology.organism_classification ,parasitic diseases ,medicine ,Artemisinin ,business ,Mode of action ,Malaria ,media_common ,medicine.drug - Abstract
In recent clinical trials acithromycin in combination with artemisinin derivatives proved to be a promising combination therapy with indifferent to synergistic interaction. The aim of the present study was the assessment of optimal combination ratios for dihydroartemisinin and azithromycin for the treatment of uncomplicated falciparum malaria. The study was conducted in Bandarban, in Southeastern Bangladesh. Plasmodium falciparum isolates collected as part of a clinical trial were cultured for 72 hours. Samples were analyzed using the HRP2 drug sensitivity assay in fixed combinations and checkerboard assays. An indifferent mode of interaction was found for the 1:500 combination of dihydroartemisinine and azithromycin. The sum fractional inhibitory concentrations (SFICs) at IC95 ranged from 0.89 to 1.16 for combination ratios of 1:500 and 1:5000, respectively. A trend towards lower SFICs was observed with rising inhibitory concentrations (i.e. at IC90 and IC95). Correlation analysis suggests a different mode of action for azithromycin as compared to traditional antimalarials.
- Published
- 2007
9. Spontaneous mutations in the Plasmodium falciparum sarcoplasmic/ endoplasmic reticulum Ca2+-ATPase (PfATP6) gene among geographically widespread parasite populations unexposed to artemisinin-based combination therapies
- Author
-
Tanabe, Kazuyuki, Zakeri, Sedigheh, Palacpac, Nirianne Marie Q, Afsharpad, Manada, Randrianarivelojosia, Milijaona, Kaneko, Akira, Marma, Aung Swi Prue, Horii, Toshihiro, Mita, Toshihiro, Laboratory of Malariology, Research Institute for Microbial Diseases, Biotechnology Research Center, Institut Pasteur d'Iran, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP), Department of Molecular Protozoology, Osaka University [Osaka]-Research Institute for Microbial Diseases, Institut Pasteur de Madagascar, Réseau International des Instituts Pasteur (RIIP), Karolinska Institutet [Stockholm], Emerging and Re-emerging Diseases, Communicable Disease Control, Directorate General of Health Services, Department of International Affairs and Tropical Medicine, Tokyo Women's Medical University (TWMU), and This work was supported by Grant-in-Aids for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan (18073013), from the Japan Society for Promotion of Sciences (18GS03140013, 20390120, 22406012), and from the Ministry of Health, Labor and Welfare (H20-Shinkou-ippan-013).
- Subjects
MESH: Mutation ,MESH: Polymorphism, Single Nucleotide ,[SDV]Life Sciences [q-bio] ,MESH: Anti-Infective Agents ,Plasmodium falciparum ,Protozoan Proteins ,MESH: Haplotypes ,Polymorphism, Single Nucleotide ,Artemisinins ,Sarcoplasmic Reticulum Calcium-Transporting ATPases ,MESH: Sarcoplasmic Reticulum Calcium-Transporting ATPases ,Anti-Infective Agents ,Gene Frequency ,Haplotypes ,Mechanisms of Resistance ,MESH: Artemisinins ,parasitic diseases ,Mutation ,MESH: Gene Frequency ,Animals ,MESH: Animals ,MESH: Protozoan Proteins ,MESH: Plasmodium falciparum - Abstract
International audience; Recent reports on the decline of the efficacy of artemisinin-based combination therapies (ACTs) indicate a serious threat to malaria control. The endoplasmic/sarcoplasmic reticulum Ca(2+)-ATPase ortholog of Plasmodium falciparum (PfSERCA) has been suggested to be the target of artemisinin and its derivatives. It is assumed that continuous artemisinin pressure will affect polymorphism of the PfSERCA gene (serca) if the protein is the target. Here, we investigated the polymorphism of serca in parasite populations unexposed to ACTs to obtain baseline information for the study of potential artemisinin-driven selection of resistant parasites. Analysis of 656 full-length sequences from 13 parasite populations in Africa, Asia, Oceania, and South America revealed 64 single nucleotide polymorphisms (SNPs), of which 43 were newly identified and 38 resulted in amino acid substitutions. No isolates showed L263E and S769N substitutions, which were reportedly associated with artemisinin resistance. Among the four continents, the number of SNPs was highest in Africa. In Africa, Asia, and Oceania, common SNPs, or those with a minor allele frequency of ≥0.05, were less prevalent, with most SNPs noted to be continent specific, whereas in South America, common SNPs were highly prevalent and often shared with those in Africa. Of 50 amino acid haplotypes observed, only one haplotype (3D7 sequence) was seen in all four continents (64%). Forty-eight haplotypes had frequencies of less than 5%, and 40 haplotypes were continent specific. The geographical difference in the diversity and distribution of serca SNPs and haplotypes lays the groundwork for assessing whether some artemisinin resistance-associated mutations and haplotypes are selected by ACTs.
- Published
- 2010
10. In vitro interaction of dihydroartemisin and lumefantrine in clinical field isolates from Bangladesh
- Author
-
Wasif A. Khan, Harald Noedl, Kamala Thriemer, Selim Akther, Peter Starzengruber, Matthias G. Vossen, Rashidul Haque, Aung Swi Prue Marma, and Mark M. Fukuda
- Subjects
Drug ,medicine.medical_treatment ,media_common.quotation_subject ,Plasmodium falciparum ,Dihydroartemisinin ,Pharmacology ,Lumefantrine ,Lethal Dose 50 ,chemistry.chemical_compound ,Antimalarials ,parasitic diseases ,Medicine ,Animals ,Humans ,Artemether ,Artemisinin ,Malaria, Falciparum ,media_common ,Bangladesh ,Fluorenes ,biology ,Dose-Response Relationship, Drug ,business.industry ,Drug Synergism ,General Medicine ,biology.organism_classification ,medicine.disease ,In vitro ,Artemisinins ,Survival Rate ,Treatment Outcome ,chemistry ,Ethanolamines ,Drug Therapy, Combination ,business ,Malaria ,medicine.drug - Abstract
The combination of artemether and lumefantrine was introduced in 2005 as the official first line therapy for uncomplicated falciparum malaria in Bangladesh. Fresh P. falciparum samples from patients with acute uncomplicated falciparum malaria who presented to the field site at the Bandarban Sadar Hospital in Bangladesh were tested in checkerboard in vitro drug sensitivity assays to assess the interaction between dihydroartemisinin (DHA) and lumefantrine (LUM). Clearly synergistic interactions with an overall mean FIC(50) of 0.52 and individual mean FICs between 0.26 and 0.85 were found. Lowest FICs were 0.41, 0.18, 0.22, 0.15 and 0.11 at different combination ratios. The optimal combination ratio of the drug combination indicated by the lowest mean FIC average was found to be 1:150 DHA:LUM. Although activity correlations between DHA and lumefantrine were significant, indicating possible cross sensitivity patterns, our data confirm that artemether-lumefantrine is a highly synergistic drug combination.
- Published
- 2007
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.